More Videos
- Reporters Barred from Ariad, Celgene, Cougar Roundtable?
- Amgen CEO To Shareholders: I Feel Your Pain, Too
- Amgen's Visit From The "Tooth Fairy" (By Way Of Root Canal?)
- Merck's Layoffs Show Pain Of Lower Drug Sales,Too Many Reps
- Pfizer "Re-Lighting" Chantix Ad Campaign For Smokers?
- Fixing Pfizer And Your Emails
- Former Merck CEO Prodding Industry On Drug Pricing
- Merck "Adapts" To Tredaptive Setback
- Regulatory "Risky Business" for Pharma & Biotech
- Amgen: Is "A" For Anemia Or Acquisition?
- What's In A Name: Kobe And Eli Up, Roger Down--And Darren?
- Hybrid Backlash: Your Comments On My "Critical" Post
- "Major League Eating: The Game" Now On Wii (And No Calories)
- Market 360: The Best and Worst of the Week for US Equities, Commodities, Currencies, and More
- Your First Move For Monday May 12th
- Web Extra: 3 Trades For Week Ahead
- Surprise Friday: Guess The Guest!
- Lightning Round OT: Fluor, Aqua America and More
- Cramer: AIG Chief Must Go
- The Fast Money Misfires – Friday May 9th
- Bonds Flat as Stock Market Looks for Direction
- IPOs in the City: Prada Vs. Ferragamo
- Sprint's Quarterly Loss Widens, Revenue Falls
- MBIA Swings to Huge Loss of $2.4 Billion
- Ford May Scrap Mercury Rather than Revive It
- HSBC Earnings, Bad Debts Rise
- Morgan Stanley Raises $4 Billion for Infrastructure
- Inflation, Housing Data Lead Busy Economic Week
- Energy Stocks, HSBC Lead Markets Higher
- European Shares Set to Open Mixed
 |
CNBC.com |
] and Schering-Plough [SGP
Loading...
(%)
] announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.Analysts didn't have high hopes for the drug (especially after the agency recently revealed it's investigating a possible association between Singulair and suicidal behavior), so investors seem to be shrugging off the news.
In fact, MRK shares are rallying this morning ahead of an anticipated FDA decision sometime today on its cholesterol drug called Cordaptive. It's a combo of Niacin and a special ingredient to reduce the facial flushing side effects of Niacin. Analyst estimates for peak sales of Cordaptive range from a few hundred million bucks a year to billion-dollar blockbuster status.
Abbott Labs [ABT
Loading...
(%)
] makes a Niacin drug called Niaspan which could possibly take a hit if/when Cordaptive gets approved. Today is the date given as the PDUFA (Prescription Drug User Fee Act) or what, in plain English, I like to call the"action day" for an FDA Cordaptive decision in case you're wondering how people know when this kind of stuff is gonna happen.
Also late Friday, Bristol-Myers Squibb [BMY
Loading...
(%)
] and Medarex [MEDX
Loading...
(%)
] announced a regulatory delay for their skin cancer treatment. MEDX shares hit a new intra-day low earlier this morning. The FDA wants the companies to test and see if the drug helps people live longer rather than just extending the amount of time that goes by before the cancer worstens.
Meantime, after dueling data presentations at a scientific conference in Milan over the weekend, analysts are declaring Vertex Pharmaceuticals [VRTX
Loading...
(%)
] the winner versus Schering-Plough in the latest round of the Hepatitis C drug battle. Vertex is partnered with Johnson and Johnson [JNJ
Loading...
(%)
] on telaprevir. Wachovia's George Farmer calls SGP's data "underwhelming" and says VRTX's data "positions telaprevir as the (Hepatitis C drug) of choice between these two candidates." Leerink Swann's Howard Liang says Schering's drug is "in the game" but adds, "Advantage goes to telaprevir."
related content |
Hep C doesn't get much mainstream media play, but in medical and investment circles it is considered to be a big area of unmet need and a potential goldmine for drug companies that can develop better treatments. The drugs on the market today don't work on many patients and can make them feel like they have the flu. VRTX and SGP have the most mature pipeline products, but other companies are also in various earlier stages of developing Hep C drugs.
Wachovia and Leerink Swann make a market in VRTX and LS trades in SGP.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes